Entest BioMedical's Subsidiary Zander Therapeutics, Inc. Reports on Preliminary Canine Experiments Testing New Anti-Inflammatory Drug Compounds

SAN DIEGO, June 7, 2017 /PRNewswire/ --

Entest BioMedical Inc.'s (PINK: ENTB) subsidiary, Zander Therapeutics Inc. ,reported that initial data from its canine study suggest that compounds currently being tested ex vivo show promise as small molecule anti-inflammatory treatments in canines.  The Company is in the process of developing anti-cancer and anti-inflammatory drugs for the Canine, Feline and Equine markets.  David Koos, CEO of both Entest BioMedical and Zander, stated "Finding  that compounds being developed by Regen BioPharma, Inc. for modulating NR2F6 in humans appear to modulate NR2F6 in dogs is an extremely exciting development.  There can be a  direct crossover effect in drug development."

The significance of this finding is that it further supports Zander Therapeutics research for veterinary applications of compounds that modulate the checkpoint NR2F6. By modulating the checkpoint NR2F6, the Company believes it can treat autoimmune diseases, as well as cancer in animals.  Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of the small molecule modulators of checkpoint NR2F6 being developed for human use by Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP).

Based on the license agreement, Zander is able to benefit from the progress Regen BioPharma, Inc. makes in developing NR2F6 small molecule modulators for humans by testing the same drugs in animals.  In partnership with Chem Div, Inc., an internationally recognized contract research organization, Zander has tested some initial compounds that act on human cells in suppressing the immune system in a small amount of dog blood.  The results indicate that at least one of the compounds suppressed IL-17a expression in activated peripheral blood mononuclear cells in a non-toxic manner.

Zander is continuing similar experiments testing other compounds and will also begin to test anti-cancer small molecule compounds in the coming months.

The NR2F6 nuclear receptor has been identified as a potentially  extremely important immune cell inhibitor and cancer stem cell differentiator.  Molecules which function as immune cell inhibitors are called "immune checkpoints" and basically act as an "on or off switch" to an immune response.  Cancer cells sometimes find ways to use these checkpoints to avoid being attacked by the immune system therefore therapies that target these checkpoints demonstrate tremendous potential as cancer treatments. The NR2F6 program at Zander Therapeutics focuses on identifying antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a dog's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.

About Zander Therapeutics Inc. and Entest BioMedical Inc.:   

Zander Therapeutics is a subsidiary of Entest BioMedical Inc. (OTCPink: ENTB), a publicly traded biotechnology company focused on veterinary medicine. The Company seeks to develop small molecule and immune stimulating therapies for veterinary applications.

Currently, the Company's major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals, which include arthritis.

Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc.'s (OTCQB: RGBP) (OTCQB: RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as a "orphan nuclear receptor", which controls genes associated with the immune response.  Zander Therapeutics is solely focused on veterinary applications.  

David Koos serves as Chairman and Chief Executive officer of Regen BioPharma, Inc. (OTCQB: RGBP), Entest BioMedical Inc. (OTCPINK: ENTB) and Zander Therapeutics Inc. (subsidiary of Entest BioMedical Inc.).

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION
 
Zander Therapeutics Inc. and Entest BioMedical Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.zandertherapeutics.com/
[email protected]   

SOURCE Entest BioMedical Inc.